These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27275785)

  • 21. Neuroimaging in amyotrophic lateral sclerosis.
    Turner MR; Agosta F; Bede P; Govind V; Lulé D; Verstraete E
    Biomark Med; 2012 Jun; 6(3):319-37. PubMed ID: 22731907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [What are the applications of biomarkers in ALS today?].
    Blasco H; Corcia P; Pradat PF
    Presse Med; 2014 May; 43(5):569-79. PubMed ID: 24785140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New molecular diagnostic trends and biomarkers for amyotrophic lateral sclerosis.
    Pampalakis G; Mitropoulos K; Xiromerisiou G; Dardiotis E; Deretzi G; Anagnostouli M; Katsila T; Rentzos M; Patrinos GP
    Hum Mutat; 2019 Apr; 40(4):361-373. PubMed ID: 30556231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery.
    Krüger T; Lautenschläger J; Grosskreutz J; Rhode H
    Proteomics Clin Appl; 2013 Jan; 7(1-2):123-35. PubMed ID: 23129563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positron Emission Tomography Molecular Imaging Biomarkers for Amyotrophic Lateral Sclerosis.
    Chew S; Atassi N
    Front Neurol; 2019; 10():135. PubMed ID: 30881332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging techniques in ALS.
    Zaccagna F; Lucignani G; Raz E; Colonnese C
    Arch Ital Biol; 2017 Dec; 155(4):142-151. PubMed ID: 29405031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positron emission tomography neuroimaging in amyotrophic lateral sclerosis: what is new?
    Quartuccio N; Van Weehaeghe D; Cistaro A; Jonsson C; Van Laere K; Pagani M
    Q J Nucl Med Mol Imaging; 2014 Dec; 58(4):344-54. PubMed ID: 25375229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic Biomarkers and Neurodegeneration: A Pathway Enrichment Analysis of Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis.
    Kori M; Aydın B; Unal S; Arga KY; Kazan D
    OMICS; 2016 Nov; 20(11):645-661. PubMed ID: 27828769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased expression of Myosin binding protein H in the skeletal muscle of amyotrophic lateral sclerosis patients.
    Conti A; Riva N; Pesca M; Iannaccone S; Cannistraci CV; Corbo M; Previtali SC; Quattrini A; Alessio M
    Biochim Biophys Acta; 2014 Jan; 1842(1):99-106. PubMed ID: 24184715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS.
    Goyal NA; Berry JD; Windebank A; Staff NP; Maragakis NJ; van den Berg LH; Genge A; Miller R; Baloh RH; Kern R; Gothelf Y; Lebovits C; Cudkowicz M
    Muscle Nerve; 2020 Aug; 62(2):156-166. PubMed ID: 31899540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative analysis of targeted metabolomics: dominance-based rough set approach versus orthogonal partial least square-discriminant analysis.
    Blasco H; Błaszczyński J; Billaut JC; Nadal-Desbarats L; Pradat PF; Devos D; Moreau C; Andres CR; Emond P; Corcia P; Słowiński R
    J Biomed Inform; 2015 Feb; 53():291-9. PubMed ID: 25499899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Apo B48 and other novel biomarkers in amyotrophic lateral sclerosis patient fibroblasts.
    Narayan M; Seeley KW; Jinwal UK
    Biomark Med; 2016 May; 10(5):453-62. PubMed ID: 27141953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amyotrophic lateral sclerosis--the tools of the trait.
    Lederer CW; Santama N
    Biotechnol J; 2007 May; 2(5):608-21. PubMed ID: 17345579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of an Automated MRI-Based Diagnostic Protocol for Amyotrophic Lateral Sclerosis Using Disease-Specific Pathognomonic Features: A Quantitative Disease-State Classification Study.
    Schuster C; Hardiman O; Bede P
    PLoS One; 2016; 11(12):e0167331. PubMed ID: 27907080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomics, proteomics and metabolomics: their emerging roles in the discovery and validation of rheumatoid arthritis biomarkers.
    Castro-Santos P; Laborde CM; Díaz-Peña R
    Clin Exp Rheumatol; 2015; 33(2):279-86. PubMed ID: 25572119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis.
    Su XW; Simmons Z; Mitchell RM; Kong L; Stephens HE; Connor JR
    JAMA Neurol; 2013 Dec; 70(12):1505-11. PubMed ID: 24145899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective Validation of 18F-FDG Brain PET Discriminant Analysis Methods in the Diagnosis of Amyotrophic Lateral Sclerosis.
    Van Weehaeghe D; Ceccarini J; Delva A; Robberecht W; Van Damme P; Van Laere K
    J Nucl Med; 2016 Aug; 57(8):1238-43. PubMed ID: 26940764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis.
    Turner MR; Benatar M
    Muscle Nerve; 2015 Jan; 51(1):14-8. PubMed ID: 25288265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrative gene-tissue microarray-based approach for identification of human disease biomarkers: application to amyotrophic lateral sclerosis.
    Kudo LC; Parfenova L; Vi N; Lau K; Pomakian J; Valdmanis P; Rouleau GA; Vinters HV; Wiedau-Pazos M; Karsten SL
    Hum Mol Genet; 2010 Aug; 19(16):3233-53. PubMed ID: 20530642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of biomarkers in ALS drug development and clinical trials.
    Bakkar N; Boehringer A; Bowser R
    Brain Res; 2015 May; 1607():94-107. PubMed ID: 25452025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.